MARC EXILUS: Open Payments
NPI 1588149587 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$392 in 10 payments from 5 companies in 2025. Trend: 2023 $193 · 2024 $76 · 2025 $392
Food & beverage: $392
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 1 | $117 |
| Neurocrine BioSciences, Inc. | 4 | $90 |
| Otsuka America Pharmaceutical, Inc. | 2 | $84 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $62 |
| Lundbeck LLC | 2 | $39 |
Products named: SPRAVATO, INGREZZA, REXULTI, CAPLYTA, ABILIFY ASIMTUFII.
Industry payments across DE — which companies pay providers there.
